Drugs / CHS-1000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06389526 | Feb 2025 → May 2028 expected | — | Coherus Oncology, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-04-08 | Coherus Oncology, Inc. | Results Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting coherus.com ↗
The data presented in this poster demonstrate the potential for CHS-1000 to reverse myeloid suppression and activate an inflammatory immune response. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-04-08 | Coherus Oncology, Inc. | Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting coherus.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHS-1000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06389526 ↗ |